Dr. Bart Cornelissen
Bart is CRUK Junior Group Leader based at the Oxford Institute for Radiation Oncology and has headed the Radiopharmaceuticals and Molecular Imaging group since early 2013. Bart trained in analytical chemistry and radiochemistry at the Universities of Hasselt and Ghent, Belgium. He obtained his PhD in radiopharmaceutical sciences from the University of Ghent in 2004 and spent several years at the University of Toronto as a post-doctoral fellow before joining the University of Oxford in 2007.
The group aims to develop new radioisotope-labelled compounds for the imaging of tumour biology, with a focus on DNA damage repair imaging, especially in pancreatic cancer. Most molecular imaging targets are extracellular epitopes: cytokines, growth factors, or extracellular receptors. However, there is a mismatch between molecular imaging methods, which mostly target proteins or receptors on the outside of cancer cells, and cancer biology, where mostly intracellular events are studied. Therefore, one aim of the group is to develop novel methods to enable imaging of intracellular proteins, such as those involved in DNA damage repair signalling.
Dr Cornelissen has published more than 70 papers on the subject of PET and SPECT imaging in oncology, and holds several patents. He is a member of the Nuclear Medicine and Biology and Tomography editorial boards.